Skip to main content

Table 1 Characteristics of subjects

From: Beneficial association of angiotensin-converting enzyme inhibitors and statins on the occurrence of possible Alzheimer’s disease after traumatic brain injury

 

Possible AD

Non-AD

A. Analysis of association of TBI with development of dementia with possible AD

 Age

80.9 ± 6.7

70.1 ± 10.1

 Sex

  Male

62,951

556,525

  Female

1388

31,920

 Ethnicity

  Caucasian

51,884

445,237

  African American

6779

97,782

  Hispanic

4565

30,581

  Other

1111

14,845

B. Analysis of association of medications with development of dementia with possible AD after TBI occurrence

 Age

76.9 ± 8.5

64.5 ± 9.8

 Sex

  Male

310

5663

  Female

17

710

 Ethnicity

  White

228

4431

  African American

35

1243

  Hispanic

57

506

  Other

7

193

 Medication

  No med

92

1957

  ACEI

47

644

  Beta blocker

35

868

  Metformin

29

403

  Statin

57

1105

  ACEI + beta blocker

15

262

  ACEI + metformin

2

133

  ACEI + statin

14

359

  Beta blocker + statin

21

394

  Beta blocker + metformin

3

89

  Metformin + statin

12

159

  1. Note: “Medication” designates single and combination patterns of the four target medication classes. Subjects who were prescribed medications other than the target medication classes in the dataset are included as “No med” group. Subjects who were on any of those medication classes at the start of study window or were prescribed three or four of those classes are excluded